Polpharma API

Introducing #Trametinib, a highly potent API. Produced in our brand new #HPAPI facility. Thanks to the back integration with 12 in-house steps, we can maintain high control over the manufacturing process. Contact us for more details: https://lnkd.in/dhwf39Qc Disclaimer: Trametinib is protected by patents (SPC) in Poland and is developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. Trametinib is not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

Are you looking for a European #CDMO partner for your #API development and commercial supply ? Look no further! At #PolpharmaAPI, we boast an impressive 70-year legacy of #expertise fueled by a passionate and dedicated team of professionals. Our investment in a state-of-the-art facility that handles #HPAPI underscores our dedication to cutting-edge solutions.  With a rich history in the pharmaceutical industry, we possess the skills to deliver top-class products and services. Our high competencies result from our unwavering commitment to excellence as we continually push the boundaries of #innovation and #quality. Join us at CPHI 2024 in Fiera Milano, booth 24A11. Don’t wait—book a meeting with our representatives today! CDMO: cdmo@polpharma.com GENERICS: api@polpharma.com Learn more about Polpharma API: https://lnkd.in/dzedVqeG #CPHIWW #CPHI #smallmolecules #HPAPI #CDMO #TheFutureIsNow

Polpharma’s Leap in HP API CDMO Services Polpharma API is at the forefront of the transformative wave in the pharmaceutical industry. We have strategically expanded our Contract Development and Manufacturing Organization (CDMO) segment, recruiting top-tier talent in R&D and investing in state-of-the-art production equipment.   What sets us apart? Our regulatory prowess, project management excellence, and investment in cutting-edge facilities of highly-active substances. We offer comprehensive support across various phases of NCE development, from initial clinical supplies to validation, launch, and routine commercial supplies.   Connect with us at cdmo@polpharma.com to explore how Polpharma can be your strategic ally in drug substance development and manufacturing. The future is now! #HPAPI #CDMO #API

Polpharma among industry leaders in the ESG Ranking Responsible Management We are in third place in the pharmaceutical and medical industry. Sanofi-Aventis and LUX MED were on the podium, and we would like to 👏 congratulate them In the eighteenth edition of the "ESG Ranking. Responsible Management" campaign, almost 70 companies took part, and almost 150 companies expressed interest in it. Ultimately, 62 companies qualified for the main ranking. This year, the level of difficulty of the survey that was the basis for the ranking was very high, and the questions concerned all areas related to ESG reporting. The survey included 70 questions of various nature in eleven sections. The questions refer directly to the reporting guidelines under the European Sustainability Reporting Standards (ESRS).   We would like to thank the Scientific Council of the ESG Ranking for the distinction and congratulate all the 👏 winners   About the ranking "ESG ranking. Responsible Management" organized by Kozminski Business Hub in Kozminski University is a new edition of the Ranking of Responsible Companies, which for many years has been a barometer of the maturity of responsible management in the largest companies, valued on the market. Every year, the content of the survey is changed – adequately to the state of the market and the expectations of stakeholders. More on https://lnkd.in/dTMyFcRX. #Sustainability #ESG #Polpharma #PolpharmaAPI

Save the date! On June 26-27, our CDMO team will participate in the Process Development for Highly Potent Drugs Summit Conference. Philadelphia is a great place to meet us and discuss opportunities to collaborate and shape the future of healthcare together. Explore our capabilities, and let's talk about your API technology needs.   Do you already know how much Polpharma can offer?   ✔️ HP API (OEL up to 10 ng/m3) ✔️ EU manufacturing site ✔️ US FDA-approved ✔️ 70 years of experience in small molecules ✔️ cGMP manufacturing ✔️ Highest quality standards ✔️ Research, Development, and Commercial Manufacturing ✔️ World-class regulatory support ✔️ Smooth and transparent cooperation   Take advantage of this opportunity, and contact us today. We look forward to seeing you there!   Contact us:  CDMO: cdmo@polpharma.com GENERICS: api@polpharma.com #CDMO #PolpharmaAPI #HPAPI #HiglyPotent #DrugsSummitConference #Summit #Philadelphia #Oncology #USFDA

Otrzymaliśmy Srebrny Listek ESG POLITYKI Tygodnik Tygodnik Polityka we współpracy z firmą doradczą Deloitte oraz Forum Odpowiedzialnego Biznesu już po raz 13. wyróżnił polskich liderów ESG w ramach zestawienia Listków ESG POLITYKI, oceniając działalność przedsiębiorstw pod względem środowiskowym (E), społecznym (S) i ładu korporacyjnego (G). Srebrny Listek ESG otrzymują firmy, które w swojej codziennej działalności operacyjnej deklarują uwzględnianie wszystkich kluczowych rozwiązań normy ISO 26000. Firmy te często opierają się o najlepsze lokalne i globalne praktyki zarządcze oraz stosują międzynarodowe standardy. Dodatkowo istotnym elementem ich zarządzania jest system zarządzania etyką oraz najwyższe standardy zarządzania personelem. O efektach swoich działań cyklicznie informują interesariuszy m.in. poprzez raportach pozafinansowych lub zintegrowanych przygotowanych w oparciu o międzynarodowe standardy ujawniania danych. Spośród 98 zgłoszeń w rankingu wyróżnienia zdobyło 58 firm. Srebrny Listek ESG trafił do 14. Gratulujemy wszystkim firmom, które znalazły się w zestawieniu 🎉 Listek ESG Polityki to nagroda dla pracownic i pracowników Polpharmy, dzięki którym rozwijamy biznes w odpowiedzialny sposób, wdrażając najlepsze praktyki ESG, CSR i zrównoważonego rozwoju. Dziękujemy!👏 #ESG #Sustainability #Polpharma #ZrównoważonyRozwój #ESG #SpołecznaOdpowiedzialnośćBiznesu #ListkiESG

Green Process Award granted to the Polpharma API team!   The program's idea is to encourage Polpharma employees to find and implement innovations in the organization and embed the principles of Green Processes in R&D, production, and other processes. This year, 16 initiatives were submitted for the Green Process Award, and the team from our API Plant in Starogard Gdański was granted first place. Congratulations to our colleagues!   API team proposed changing the method of drying #dapagliflozin in a mixer-dryer. Thanks to the initiative, the process time was shortened from 25 days to 3 days. The change increased production capacity, unblocked the drying node, and increased the line's efficiency. This helped to achieve savings in electricity and heating steam.   Dapagliflozin is one of the most critical molecules in treating type 2 diabetes. Dapagliflozin and other drugs from the flozin group significantly improve the quality of life of patients and facilitate uninterrupted daily therapy.    Check our diabetes pipeline:    #greenprocess We always look for solutions that improve the eco-efficiency of production processes, products, or services.   Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on the exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products, products, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

#Linagliptin Effective and well-tailored pharmacotherapy in #type2diabetes is crucial for patients well-being. One of the most important treatment options is #Linagliptin, providing flexibility as it can be taken both as monotherapy and in combination with other drugs. #Linagliptin therapy offers multiple benefits, including: - consistent blood sugar control and a reduced risk of hypoglycemia - linagliptin does not affect renal function, making it a safer choice for patients with kidney concerns. - oral form ensures ease of administration, integrating seamlessly into daily routines. #Linagliptin stands out as a patient-friendly therapy, emphasizing comfort and convenience in #diabetescare. Check out our wide diabetes portfolio https://lnkd.in/eS6ZxJYf Contact us: api@polpharma.com

Polpharma API- your European #CDMO partner. Don't miss the opportunity to meet in Philadelphia on June 26-27th at the Process Development for Highly Potent Drugs Summit.   Polpharma API means: ✔️ HP API (OEL below 10 ng/m3) ✔️ EU manufacturing site ✔️ US FDA-approved ✔️ 70 years of experience in small molecules ✔️ cGMP manufacturing ✔️ Highest quality standards ✔️ Research, Development, and Commercial Manufacturing ✔️ World-class regulatory support ✔️ Smooth and transparent cooperation   Take advantage of this opportunity to stay ahead in the rapidly evolving pharmaceutical landscape! Join us for this exciting event to discuss your API needs, explore collaboration opportunities, and shape the future of healthcare together. We look forward to seeing you there! Contact us:  CDMO: cdmo@polpharma.com GENERICS: api@polpharma.com   #CDMO #HPAPI #ProcessDevelopmentforHighlyPotentDrugsSummit #PolpharmaAPI #USFDA #TheFutureIsNo #Research #Development #CommercialManufacturing

Polpharma API in cooperation with #Waters has implemented the most advanced analytical instrumentation for method development and testing of impurities to comply with evolving regulatory guidance on controlling N-nitrosamines in APIs. Read the full article to learn more https://lnkd.in/edF3ZeC8 Polpharma API, your trusted partner with over 70 years of experience, ✔️ HP API ✔️ European manufacturing sites ✔️ FDF ✔️ cGMP manufacturing ✔️ Research, Development, and Commercial Manufacturing ✔️ Highest quality standards ✔️ World-class regulatory support ✔️ Smooth and transparent cooperation The Futute Is Now Contact Us:  CDMO: cdmo@polpharma.com GENERICS: api@polpharma.com